SCHEMBL23272832

SCHEMBL23272832

C[Si](C)(C)Oc1cccc(Nc2ccc(OCc3ccccn3)cc2C2CC2)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TYK2 P29597 1/20 0.39
▸ JAK3 P52333 1/20 0.39
▸ BRD4 O60885 1/20 0.39
▸ CREBBP Q92793 1/20 0.39
▸ DGAT1 O75907 1/20 0.39
▸ EGFR P00533 2/20 0.39
▸ ERBB2 P04626 2/20 0.39
▸ CNR2 P34972 3/20 0.38
▸ MCHR1 Q99705 1/20 0.38
▸ HRH3 Q9Y5N1 1/20 0.38
▸ RHOA P61586 1/20 0.37
▸ SYK P43405 2/20 0.37
▸ AURKB Q96GD4 1/20 0.37
▸ INCENP Q9NQS7 1/20 0.37
▸ ERBB4 Q15303 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.37
▸ LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31504427 1.00 TYK2 (0.39) TYK2JAK3BRD4CREBBPDGAT1
SCHEMBL23307998 0.88 EGFR (0.39) TYK2JAK3BRD4CREBBPDGAT1
SCHEMBL21617195 0.87 MET (0.44) TYK2JAK3DGAT1EGFRERBB2
SCHEMBL21623453 0.87 EGFR (0.41) TYK2JAK3BRD4CREBBPDGAT1
SCHEMBL31504421 0.87 EGFR (0.41) TYK2JAK3BRD4CREBBPDGAT1
SCHEMBL21623513 0.86 EGFR (0.43) TYK2JAK3DGAT1EGFRERBB2
SCHEMBL31504332 0.86 EGFR (0.43) TYK2JAK3DGAT1EGFRERBB2
SCHEMBL21623405 0.86 CNR2 (0.39) TYK2JAK3DGAT1EGFRERBB2
SCHEMBL31504346 0.86 CNR2 (0.39) TYK2JAK3DGAT1EGFRERBB2
SCHEMBL21623448 0.85 DGAT1 (0.40) TYK2JAK3DGAT1CNR2MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3820850-B1 PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION ABIVAX (FR) 2026-04-01 — — EP disclosed
US-12421206-B2 Aryl-n-aryl derivatives for treating a RNA virus infection ABIVAX (FR) 2025-09-23 — — US disclosed
US-20210122732-A1 ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION ABIVAX (FR) 2021-04-29 — — US disclosed
US-20210122732-A1 ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION ABIVAX (FR) 2021-04-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12421206-B2 Aryl-n-aryl derivatives for treating a RNA virus infection NSUN3, CBR3, C1R TYK2 2212/4885JAK3 933/4885BRD4 1187/4885
US-20210122732-A1 ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION NSUN3, CBR3, C1R TYK2 2212/4885JAK3 933/4885BRD4 1187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback